Quarterly Result15 May 2026, 04:15 pm
Sanjivani Paranteral FY26: EBITDA at ₹114 mn, PAT at ₹66.94 mn
AI Summary
Sanjivani Paranteral Ltd (BSE: 531569) reported its audited financial results for FY26. The company's total income stood at ₹697.56 mn, with EBITDA at ₹114.00 mn and PAT at ₹66.94 mn. The EBITDA margin was 16.34%, and the PAT margin was 9.60%. The company's injectables segment contributed 53.45% to revenue, while tablets grew by approximately 7.5% YoY. Exports contributed 78.50% of revenue. Commercial production commenced at the new IV Fluid Infusion Plant in Pune.
Key Highlights
- FY26 Total Income: ₹697.56 mn; EBITDA: ₹114.00 mn; PAT: ₹66.94 mn.
- EBITDA margin stood at 16.34% and PAT margin at 9.60% for FY26.
- Injectables contributed 53.45% of FY26 revenue, tablets grew ~7.5% YoY.
- Exports contributed 78.50% of FY26 revenue from operations.
- Commercial production started at the new IV Fluid Infusion Plant in Pune.
Price Impact
More from SANJIVIN